Uncategorized Armata Receives Up to $5M From CF Foundation to Develop Phage Therapy AP-PA02 20 Mar 2020 The Cystic Fibrosis Foundation has awarded up to $5 million to Armata Pharmaceuticals to advance its potential treatment AP-PA02 — a phage therapy against multidrug-resistant Pseudomonas aeruginosa infections in cystic…
PHAGElogist 